Bionomics Limited (ASX:BNO)


right-arrow Created with Sketch. 0.003 (3.49%)
MCAP $120.4M
Last trade 15.51pm 28/01/2022 20mins delayed

Latest Announcements

28/01/2022 Price SensitivePSBNOBionomics Limited
19/01/2022BNOBionomics Limited
19/01/2022BNOBionomics Limited
14/01/2022BNOBionomics Limited
14/01/2022BNOBionomics Limited
11/01/2022BNOBionomics Limited
10/01/2022BNOBionomics Limited
06/01/2022BNOBionomics Limited

Company Overview

Bionomics Limited is an Australia-bases clinical-stage biopharmaceutical company. The Company is engaged in discovery and development of novel drug candidates focused on the treatment of central nervous system disorders. The Company's segment includes Drug discovery and development and Contract services. Drug discovery and development segment includes discovery, development, and commercialization of compounds to match a target product profile. Contract services segment includes provision of scientific services on a fee for service basis to both external and internal customers. Its product candidates include BNC210, BNC375, BNC101 and BNC105. The BNC210 provides treatment for anxiety disorders, co-morbid anxiety, and depression. The BNC375 is a molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease (AD).The Company operates in three geographical areas, such as Australia, France and United States of America.

BNO in the news

Bionomics (BNO) initiates a trial to evaluate a tablet for patients suffering…
Bionomics (BNO) is set to raise almost $16 million to support its…
Biopharmaceutical company Bionomics (BNO) has initiated trials to test a new tablet…
Biopharma company Bionomics (BNO) has successfully tapped institutions for almost $900,000 in…

Search Previous Announcements